CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services

jump over right navigation bar
TB Notes 2, 2008
Director's Letter
Highlights from State and Local Programs
  TB Housing Village for Homeless Patients, Yuma County, Arizona
  Public Health and Correctional Partnership in Georgia
Laboratories Offering QFT Testing
Strategies for Targeted Testing and Treatment for Latent Tuberculosis Infection: Applying ATS/CDC Guidelines to a Best Practice Evaluation
TB Education and Training Network Updates
  Member Highlight
  New Steering Committee Member
  Ask the Experts
  Correction to Error in Previous “Ask the Experts” Column
  TB ETN Cultural Competency Workgroup Update
  TB ETN Membership Is Global
  Training and Education Resources for BCG Vaccine
Communications, Education, and Behavioral Studies Branch Update
  Teachback Methodology: An Award-Winning Curriculum for Training Trainers
Clinical and Health Systems Research Branch Updates
  Study 26 Reaches Enrollment Goal
  Tuberculosis Diagnosis at Death Among HIV-Infected Persons: US Metropolitan Statistical Areas, 1998–2003
  New Publication to Arrive Soon
Mycobacteriology Laboratory Branch Update
  Expert Panel Meets to Discuss Drug Susceptibility Testing
Surveillance, Epidemiology, and Outbreak Investigations Branch Updates
  SEOIB Welcomes Three Graduate Students
  12th Semiannual Meeting of the Tuberculosis Epidemiologic Studies Consortium
New CDC Publications
Personnel Notes
Calendar of Events
Return to Table of Contents

TB Notes Newsletter

No. 2, 2008

Mycobacteriology Laboratory Branch Update

Expert Panel Meets to Discuss Drug Susceptibility Testing

A meeting hosted by CDC and the Association of Public Health Laboratories (APHL) was held December 12-13, 2007, in Atlanta to address issues regarding drug susceptibility testing of M. tuberculosis clinical isolates. The expert panel consisted of representatives from several different organizations and health entities including public health, clinical, and commercial laboratories, clinicians, the American Society for Microbiology, the Clinical and Laboratory Standards Institute (CLSI), the World Health Organization (WHO), APHL, and CDC.

During the 2-day meeting, panel members discussed recommendations for updating CLSI M24-A (Susceptibility Testing of Mycobacteria, Nocardiae, and Other Aerobic Actinomycetes; Approved Standard) that included first- and second-line drug panels and testing algorithms. Further discussions focused on the potential establishment of regional centers of excellence to provide access to accurate and reliable second-line drug testing, recommendations for ensuring proficiency of public health laboratories, guidance on referral strategies to ensure rapid testing and reporting, and the issue of discordant results between laboratories. The panel compiled an inventory of critical research needs aimed at improving current laboratory practices important for the detection and control of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB. Specific and detailed recommendations from the meeting will be forthcoming.

—Reported by Angela Starks, PhD
Div of TB Elimination


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333